Kalvista Competitors
| KALV Stock | USD 14.40 0.58 3.87% |
Kalvista Pharmaceuticals vs RAPT Therapeutics Correlation
Weak diversification
The correlation between Kalvista Pharmaceuticals and RAPT is 0.39 (i.e., Weak diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Kalvista Pharmaceuticals and RAPT in the same portfolio, assuming nothing else is changed.
Moving together with Kalvista Stock
Moving against Kalvista Stock
| 0.73 | GNLX | Genelux Common | PairCorr |
| 0.73 | KRRO | Frequency Therapeutics | PairCorr |
| 0.71 | QSI | QuantumSi | PairCorr |
| 0.71 | IMRN | Immuron Ltd ADR | PairCorr |
| 0.64 | EDIT | Editas Medicine | PairCorr |
Kalvista Pharmaceuticals Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Kalvista Pharmaceuticals and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Kalvista and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Kalvista Pharmaceuticals does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Kalvista Stock performing well and Kalvista Pharmaceuticals Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Kalvista Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| GOSS | 4.04 | 0.17 | 0.02 | (0.16) | 4.86 | 8.77 | 27.11 | |||
| FDMT | 3.97 | (0.38) | 0.00 | (0.30) | 0.00 | 6.52 | 27.09 | |||
| PRTA | 2.32 | (0.40) | 0.00 | (0.22) | 0.00 | 4.76 | 13.99 | |||
| BCYC | 2.93 | (0.60) | 0.00 | (0.60) | 0.00 | 5.51 | 14.20 | |||
| OMER | 5.61 | 1.02 | 0.19 | 3.22 | 4.52 | 12.62 | 87.69 | |||
| VSTM | 3.83 | (0.49) | 0.00 | (5.75) | 0.00 | 5.83 | 29.76 | |||
| RIGL | 3.89 | 0.18 | 0.05 | 0.15 | 4.02 | 8.66 | 44.65 | |||
| OLMA | 6.28 | 2.54 | 0.60 | (0.70) | 3.05 | 9.82 | 145.73 | |||
| ADCT | 3.34 | (0.15) | 0.00 | (0.08) | 0.00 | 8.49 | 22.84 | |||
| RAPT | 3.92 | 1.36 | 0.32 | (0.48) | 2.99 | 7.87 | 64.05 |
Cross Equities Net Income Analysis
Compare Kalvista Pharmaceuticals and related stocks such as Gossamer Bio, 4D Molecular Therapeutics, and Prothena plc Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GOSS | (83 K) | (83 K) | (83 K) | (83 K) | (83 K) | (83 K) | (83 K) | (6.8 M) | (147 M) | (180.8 M) | (243.4 M) | (234 M) | (229.4 M) | (179.8 M) | (56.5 M) | (50.9 M) | (53.4 M) |
| FDMT | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | (9.6 M) | (49.3 M) | (56.7 M) | (68.3 M) | (101.1 M) | (100.8 M) | (160.9 M) | (144.8 M) | (137.5 M) |
| PRTA | (12.5 M) | (29.7 M) | (41.4 M) | (41 M) | (7.2 M) | (80.6 M) | (160.1 M) | (153.2 M) | (155.6 M) | (77.7 M) | (111.1 M) | 67 M | (116.9 M) | (147 M) | (122.3 M) | (110.1 M) | (115.6 M) |
| BCYC | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (16.3 M) | (21.8 M) | (30.6 M) | (51 M) | (66.8 M) | (112.7 M) | (180.7 M) | (169 M) | (152.1 M) | (144.5 M) |
| OMER | (7.4 M) | (28.5 M) | (38.4 M) | (39.8 M) | (73.7 M) | (75.1 M) | (66.7 M) | (53.5 M) | (126.8 M) | (84.5 M) | (138.1 M) | (111.4 M) | 47.4 M | (117.8 M) | (156.8 M) | (141.1 M) | (134.1 M) |
| VSTM | (786 K) | (13.7 M) | (32 M) | (41.2 M) | (53.4 M) | (57.9 M) | (36.4 M) | (67.8 M) | (72.4 M) | (149.2 M) | (67.7 M) | (71.2 M) | (73.8 M) | (87.4 M) | (130.6 M) | (117.6 M) | (111.7 M) |
| RIGL | (12.4 M) | (86 M) | (98.8 M) | (89 M) | (90.9 M) | (51.5 M) | (69.2 M) | (78 M) | (70.5 M) | (66.5 M) | (29.7 M) | (17.9 M) | (58.6 M) | (25.1 M) | 17.5 M | 15.7 M | 16.5 M |
| OLMA | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (4.3 M) | (22.1 M) | (71.1 M) | (102.6 M) | (96.7 M) | (129.5 M) | (116.5 M) | (110.7 M) |
| ADCT | (89.9 M) | (89.9 M) | (89.9 M) | (89.9 M) | (89.9 M) | (89.9 M) | (89.9 M) | (89.9 M) | (123.1 M) | (116.5 M) | (246.3 M) | (230 M) | (157.1 M) | (240.1 M) | (157.8 M) | (142.1 M) | (149.2 M) |
| RAPT | (29.1 M) | (29.1 M) | (29.1 M) | (29.1 M) | (29.1 M) | (29.1 M) | (29.1 M) | (29.1 M) | (36.1 M) | (43 M) | (52.9 M) | (68.2 M) | (81.9 M) | (116.8 M) | (129.9 M) | (116.9 M) | (111 M) |
Kalvista Pharmaceuticals and related stocks such as Gossamer Bio, 4D Molecular Therapeutics, and Prothena plc Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Kalvista Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Kalvista Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Kalvista Pharmaceuticals Competitive Analysis
The better you understand Kalvista Pharmaceuticals competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Kalvista Pharmaceuticals' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Kalvista Pharmaceuticals' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Kalvista Pharmaceuticals Competition Performance Charts
Five steps to successful analysis of Kalvista Pharmaceuticals Competition
Kalvista Pharmaceuticals' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Kalvista Pharmaceuticals in relation to its competition. Kalvista Pharmaceuticals' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Kalvista Pharmaceuticals in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Kalvista Pharmaceuticals' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Kalvista Pharmaceuticals, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Kalvista Pharmaceuticals position
In addition to having Kalvista Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Insurance Providers Thematic Idea Now
Insurance Providers
Companies providing all types of insurance and insurance services. The Insurance Providers theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Insurance Providers Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Kalvista Stock Analysis
When running Kalvista Pharmaceuticals' price analysis, check to measure Kalvista Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kalvista Pharmaceuticals is operating at the current time. Most of Kalvista Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kalvista Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kalvista Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kalvista Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.